TWI891129B - 投與抗纖維化療法之方法 - Google Patents

投與抗纖維化療法之方法

Info

Publication number
TWI891129B
TWI891129B TW112145288A TW112145288A TWI891129B TW I891129 B TWI891129 B TW I891129B TW 112145288 A TW112145288 A TW 112145288A TW 112145288 A TW112145288 A TW 112145288A TW I891129 B TWI891129 B TW I891129B
Authority
TW
Taiwan
Prior art keywords
compound
auc
individual
hours
subject
Prior art date
Application number
TW112145288A
Other languages
English (en)
Chinese (zh)
Other versions
TW202412795A (zh
Inventor
林 潘
桃樂絲 紫芸 鐘
傑佛瑞 馬克 哈里斯
印第安娜 史東布
Original Assignee
美商基因科技公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商基因科技公司 filed Critical 美商基因科技公司
Publication of TW202412795A publication Critical patent/TW202412795A/zh
Application granted granted Critical
Publication of TWI891129B publication Critical patent/TWI891129B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW112145288A 2016-11-30 2017-11-29 投與抗纖維化療法之方法 TWI891129B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662428163P 2016-11-30 2016-11-30
US62/428,163 2016-11-30
US201662432425P 2016-12-09 2016-12-09
US62/432,425 2016-12-09

Publications (2)

Publication Number Publication Date
TW202412795A TW202412795A (zh) 2024-04-01
TWI891129B true TWI891129B (zh) 2025-07-21

Family

ID=60655162

Family Applications (3)

Application Number Title Priority Date Filing Date
TW112145288A TWI891129B (zh) 2016-11-30 2017-11-29 投與抗纖維化療法之方法
TW106141628A TWI826361B (zh) 2016-11-30 2017-11-29 投與抗纖維化療法之方法
TW114123565A TW202539656A (zh) 2016-11-30 2017-11-29 投與抗纖維化療法之方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW106141628A TWI826361B (zh) 2016-11-30 2017-11-29 投與抗纖維化療法之方法
TW114123565A TW202539656A (zh) 2016-11-30 2017-11-29 投與抗纖維化療法之方法

Country Status (11)

Country Link
US (3) US11207304B2 (enExample)
EP (2) EP3548025A1 (enExample)
JP (3) JP2020502054A (enExample)
KR (3) KR20230129628A (enExample)
CN (1) CN110087651A (enExample)
AU (3) AU2017366881A1 (enExample)
CA (2) CA3045455A1 (enExample)
IL (3) IL299447A (enExample)
MX (3) MX2019006143A (enExample)
TW (3) TWI891129B (enExample)
WO (1) WO2018102323A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI891129B (zh) 2016-11-30 2025-07-21 美商基因科技公司 投與抗纖維化療法之方法
CN114129517A (zh) * 2020-09-03 2022-03-04 苏州爱科百发生物医药技术有限公司 一种ak3287制剂及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
RU2692485C2 (ru) * 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
TWI891129B (zh) 2016-11-30 2025-07-21 美商基因科技公司 投與抗纖維化療法之方法

Also Published As

Publication number Publication date
EP4470624A3 (en) 2025-01-08
AU2025238129A1 (en) 2025-10-23
AU2017366881A1 (en) 2019-05-30
EP4470624A2 (en) 2024-12-04
KR20220139450A (ko) 2022-10-14
WO2018102323A1 (en) 2018-06-07
TW201825093A (zh) 2018-07-16
JP2020502054A (ja) 2020-01-23
AU2023263548B2 (en) 2025-10-16
US20240197693A1 (en) 2024-06-20
TW202539656A (zh) 2025-10-16
IL289544A (en) 2022-03-01
AU2023263548A1 (en) 2023-11-30
IL289544B2 (en) 2023-06-01
TWI826361B (zh) 2023-12-21
JP2022058873A (ja) 2022-04-12
TW202412795A (zh) 2024-04-01
MX2020011766A (es) 2020-11-24
US11925624B2 (en) 2024-03-12
US11207304B2 (en) 2021-12-28
IL266480A (en) 2019-07-31
KR20190089862A (ko) 2019-07-31
CN110087651A (zh) 2019-08-02
JP7495951B2 (ja) 2024-06-05
US12310951B2 (en) 2025-05-27
KR20230129628A (ko) 2023-09-08
CA3247781A1 (en) 2025-07-09
IL299447A (en) 2023-02-01
US20190321344A1 (en) 2019-10-24
US20220184046A1 (en) 2022-06-16
KR102575344B1 (ko) 2023-09-06
CA3045455A1 (en) 2018-06-07
MX2023003924A (es) 2023-04-26
JP2023139157A (ja) 2023-10-03
MX2019006143A (es) 2019-10-17
EP3548025A1 (en) 2019-10-09

Similar Documents

Publication Publication Date Title
JP6456890B2 (ja) ナルトレキソン療法における薬物バイオアベイラビリティの増加
US12310951B2 (en) Methods of administering anti-fibrotic therapy
US20220105087A1 (en) Increasing Drug Bioavailability In Naltrexone Therapy
HK40012787A (en) Methods of administering anti-fibrotic therapy
TW201323014A (zh) 遮味醫藥組合物